KAISA PROSPER (02168) announced its annual performance, with a net profit attributable to shareholders of 13.198 million yuan, a decrease of 9.45% year-on-year.
Kaisa Group (02168) announced its annual financial performance ending on December 31, 2025. The group achieved a revenue of 1.612 billion RMB (same unit), a decrease of 7.14% year-on-year; the net profit attributable to owners of the company was 13.198 million RMB, a decrease of 9.45% year-on-year; earnings per share was 0.09 yuan.
KAISA PROSPER (02168) released its annual performance report for the year ending December 31, 2025. The group achieved a revenue of RMB 1.612 billion, a decrease of 7.14% compared to the previous year. The profit attributable to owners of the company was RMB 13.198 million, a decrease of 9.45% compared to the previous year. Earnings per share were RMB 0.09.
In 2025, facing a complex and challenging macroeconomic situation, KAISA PROSPER maintained stable management scale through a dual drive of "internal growth + independent expansion". The managed area is approximately 99.07 million square meters, with a total of 718 managed projects in 20 provinces and 78 cities.
Related Articles

TRIGIANT (01300) released its annual performance, with a net profit of 105 million yuan, turning losses into profits compared to the previous year.

China Securities Co., Ltd. (06066): Mai Baowen has been appointed as the joint company secretary and will act as the legal process document agent.

APEX ACE HLDG (06036) announces annual performance, with a net profit attributable to shareholders of HK$66.55 million, representing a year-on-year increase of 890.25%.
TRIGIANT (01300) released its annual performance, with a net profit of 105 million yuan, turning losses into profits compared to the previous year.

China Securities Co., Ltd. (06066): Mai Baowen has been appointed as the joint company secretary and will act as the legal process document agent.

APEX ACE HLDG (06036) announces annual performance, with a net profit attributable to shareholders of HK$66.55 million, representing a year-on-year increase of 890.25%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


